While the maintenance of a Buy rating suggests continued confidence in Sutro Biopharma's fundamentals and potential growth, the reduction in the price target could indicate concerns about near-term challenges or a recalibration of valuation expectations. This mixed signal might lead to short-term uncertainty among investors, potentially causing volatility in the stock's price.